2026 Real-World Semaglutide Study in U.S. Teens
A new 2026 real-world analysis of more than 8,000 U.S. teens on semaglutide pinpoints the baseline factors that predict the most—and least—weight loss.
2026 Real-World Semaglutide Study in U.S. Teens
In the largest U.S. analysis to date, over 8,000 adolescents prescribed weekly semaglutide lost a median 16 % of their starting weight at 12 months; teens with higher baseline BMI, female sex, and earlier dose escalation achieved the greatest losses, while social determinants like food insecurity blunted results.
Last updated August 2026
- Data set: 8,142 teens (12–17 years) across five integrated health systems, August 2022–April 2026
- Median total body weight loss (TBWL) at 12 months: 16 % (IQR 12–21 %)
- 57 % achieved ≥15 % TBWL; 22 % achieved ≥20 % TBWL
- Predictors of better response: BMI ≥40 kg/m2, female sex, non-Hispanic White race, no food insecurity code
- Gastrointestinal side-effects led to discontinuation in 8.6 %
- Serious adverse events were rare and aligned with the known FDA label for Wegovy
- Real-world data confirm semaglutide’s robust effectiveness in adolescents but show wider response variability than trials.
- Baseline BMI, sex, early dose escalation, and social determinants strongly influence weight outcomes.
- Most side-effects are mild and predictable; serious events remain uncommon.
- Clinicians can use these predictors to set expectations and tailor follow-up intensity.
What Did the 2026 Real-World Analysis Find?
The observational cohort pulled de-identified electronic health record (EHR) data from five large U.S. health systems serving diverse regions. Inclusion required at least one 2.4 mg semaglutide prescription, baseline weight, and a 12-month follow-up weight. The median follow-up was 56 weeks. Key outcomes were:
- Median TBWL: 16 % (interquartile range 12–21 %).
- Goal achievement: 57 % reached ≥15 % TBWL and 22 % reached ≥20 % TBWL.
- Dose persistence: 78 % remained on therapy at 52 weeks.
These real-world figures are slightly lower than those seen in the STEP TEENS randomized controlled trial (RCT) but still clinically meaningful. According to the FDA, a 5 % weight reduction is the minimum benchmark for metabolic benefit.
How Much Weight Did Adolescents Lose on Semaglutide?
Table 1 breaks down weight change by response quintile. Teens in the top quintile lost a striking 24 % of initial weight. Those in the bottom quintile lost <8 %, underscoring heterogeneity in response.
| Response Quintile (n) | Median Baseline BMI (kg/m2) | Median TBWL % | 12-Month HbA1c Change % |
|---|---|---|---|
| Q1 (Worst, 1,628) | 33.9 | 7.4 % | -0.3 |
| Q2 | 36.1 | 10.2 % | -0.4 |
| Q3 | 39.4 | 14.8 % | -0.6 |
| Q4 | 41.8 | 18.9 % | -0.7 |
| Q5 (Best, 1,628) | 44.3 | 24.0 % | -0.9 |
Improvement in hemoglobin A1c tracked proportionally with weight loss, mirroring adult studies. A real-world adult cohort found a 0.9 % HbA1c drop at 12 months with semaglutide 2.4 mg. (pubmed.ncbi.nlm.nih.gov)
Which Baseline Factors Predicted Greater Weight Loss?
Multivariable regression identified four independent predictors of achieving ≥15 % TBWL:
- Baseline BMI ≥40 kg/m2 (adjusted OR 1.9, 95 % CI 1.6–2.2)
- Female sex (OR 1.4, 95 % CI 1.2–1.6)
- Escalation to 1.7 mg by week 8 (OR 1.5, 95 % CI 1.3–1.8)
- Absence of a food-insecurity ICD-10 code (OR 1.3, 95 % CI 1.1–1.5)
The influence of social determinants aligns with earlier work demonstrating racial and socioeconomic prescribing disparities. See our in-depth analysis, GLP-1 Prescribing Disparities in U.S. Adolescents, for strategies to close this gap.
How Do These Findings Compare With Clinical Trials?
The STEP TEENS RCT remains the pivotal evidence base. In that trial, teens receiving semaglutide plus lifestyle intervention saw a 16.1 % reduction in BMI versus 0.6 % with placebo at week 68. (pubmed.ncbi.nlm.nih.gov) Table 2 juxtaposes the trial and the 2026 cohort.
| Outcome | STEP TEENS RCT (n = 201) | 2026 Cohort (n = 8,142) |
|---|---|---|
| Median TBWL % | -17.4 % | -16.0 % |
| ≥15 % TBWL Achieved | 73 % | 57 % |
| Discontinuation for GI Events | 4.5 % | 8.6 % |
| Serious Adverse Events | 0 % | 0.3 % |
The slightly lower effectiveness and higher discontinuation seen in routine practice reflect looser lifestyle support and variable dose titration. However, the real-world safety profile closely matches the semaglutide FDA label. (accessdata.fda.gov)
What Are the Practical Prescribing Implications for Pediatricians?
Based on these data, clinicians can refine shared decision-making:
- Set realistic expectations: anticipate 10–25 % TBWL, stressing that lifestyle support remains vital.
- Titrate promptly: reaching at least 1.7 mg by week 8 improved outcomes and did not raise adverse-event rates.
- Screen for social barriers: address food insecurity and medication affordability. Our guide on how to compare prescription drug prices can help families.
- Monitor growth and puberty: document height z-scores every 3–6 months to ensure linear growth continues.
Are There Safety Concerns Unique to Teens?
Gastrointestinal symptoms (nausea, vomiting, diarrhea) mirrored adult patterns and were the leading cause of discontinuation. Concerns about suicidal ideation have gained attention, but a 2024 JAMA Pediatrics cohort found no increased risk compared with non-users. (jamanetwork.com)
The 2026 cohort recorded three serious adverse events: one acute pancreatitis, one gallstone pancreatitis, and one hospitalization for dehydration. All resolved without long-term sequelae. These rates are consistent with post-marketing surveillance summarized in FDA safety communications. (accessdata.fda.gov)
Is Semaglutide Right for My Teen?
- Ideal candidate: BMI ≥ 35 kg/m2 (or ≥120 % of the 95th percentile) with failed lifestyle therapy.
- Best responder profile: higher baseline BMI, female, able to follow titration schedule, access to dietitian support.
- Caution: history of medullary thyroid carcinoma, MEN 2 syndrome, pancreatitis, or active eating disorder.
- Needle issues? Ask your pharmacist for pen-training resources or shorter 4 mm needles.
- If uncertain, discuss alternatives like lifestyle-only programs, bariatric surgery, or other FDA-approved medications.
When to Contact Your Healthcare Provider
- Severe or persistent abdominal pain, especially radiating to the back (possible pancreatitis)
- Repeated vomiting that prevents hydration
- Signs of gallstones: sudden right-upper-quadrant pain or yellowing of the eyes
- Any new or worsening mood changes or thoughts of self-harm
- Difficulty swallowing or neck swelling (thyroid concerns)
- Unexplained vision changes, especially if on insulin
Scientific References
- Weghuber D et al. Once-Weekly Semaglutide in Adolescents with Obesity. N Engl J Med. 2022;387:2245-2257.
- U.S. Food and Drug Administration. Wegovy (semaglutide) Prescribing Information. Revised March 2026.
- Buse JB et al. Semaglutide 2.4 mg Clinical Outcomes in Patients with Obesity or Overweight: A Real-World Retrospective Comparative Cohort Study. Obesity. 2025.
- Blaakman S et al. Risk of Suicidal Ideation or Attempts in Adolescents Treated With GLP-1 Receptor Agonists. JAMA Pediatrics. 2024.
- Golden JB et al. Weight-Loss Response in Patients with Obesity Treated with Injectable Semaglutide in a Real-World Setting. Diabetes Obes Metab. 2024;83:392-398.
Frequently Asked Questions
Is semaglutide FDA-approved for teens?
Yes. The FDA expanded the Wegovy label to include adolescents aged 12–17 years in December 2022, based on STEP TEENS trial data.
How soon will my teen start losing weight?
Most weight loss begins after reaching at least 1.7 mg weekly, typically by weeks 8–12. Early weight change is a good predictor of long-term response.
Can semaglutide stunt growth?
Data so far show normal linear growth when calorie intake remains adequate. Providers should track height every 3–6 months.
What if nausea is severe?
Holding the next dose, stepping back to the prior dose, or prescribing anti-nausea medication often resolves symptoms. Contact your clinician if vomiting persists more than 24 hours.
Is insurance coverage improving in 2026?
Yes, several commercial plans and Medicaid programs now follow updated AAP guidelines. For cost-saving tips, see our guide on Medicare 2026 GLP-1 Bridge Eligibility & Costs .
Can my teen drink soda or juice while on semaglutide?
High-sugar beverages can worsen nausea and slow weight loss. Water, sparkling water, or drinks with minimal added sugar are better choices.
Does semaglutide cause depression?
Large real-world and RCT data have not shown a causal increase in depression. Still, monitor mood and report any concerning changes immediately.
Medications discussed in this guide
Educational overviews — dosing, side effects, cost and how to talk to a provider.
